For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, pyrotinib plus capecitabine offers an overall survival benefit.
THURSDAY, Nov. 16, 2023 (HealthDay News) For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, pyrotinib plus capecitabine offers an overall survival benefit, according to a study presented at the Advanced Breast Cancer Seventh International Consensus Conference, held from Nov. 9 to 11 in Lisbon, Portugal. Binghe Xu, M.D., from
Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the longest follow-up of the PHOEBE randomized clinical trial in China.
Latest results from clinical trial show patients with advanced HER2-positive breast cancer live longer on pyrotinib medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
<p>Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the longest follow-up of the PHOEBE randomised clinical trial in China. Presenting the latest results at the Advanced Breast Cancer Seventh International Consensus Conference (ABC 7), Professor Xichun Hu, of Fudan University Cancer Hospital, Shanghai, China, said the researchers had been able to analyse data on overall survival from the trial up to March 15, 2023.</p>